Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib with POMP/D Maintenance for ALL/LBL/MPAL
NCT02578511Phase 1Withdrawn
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and mixed phenotype acute leukemia (MPAL). Primary endpoint: Maximum Tolerated Dose at 8 weeks. Planned start Jun 2017; status: withdrawn.
02
Drugs
ixazomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT02578511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02578511.